Compugen (CGEN) to Release Quarterly Earnings on Tuesday

Compugen (NASDAQ:CGEN - Get Free Report) is scheduled to be releasing its earnings data before the market opens on Tuesday, November 12th. Analysts expect Compugen to post earnings of $0.21 per share for the quarter. Persons interested in listening to the company's earnings conference call can do so using this link.

Compugen (NASDAQ:CGEN - Get Free Report) last released its quarterly earnings data on Tuesday, August 6th. The biotechnology company reported ($0.02) earnings per share for the quarter, topping analysts' consensus estimates of ($0.08) by $0.06. The business had revenue of $6.70 million during the quarter, compared to analyst estimates of $2.68 million. During the same quarter in the previous year, the company earned ($0.11) EPS. On average, analysts expect Compugen to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Compugen Price Performance

Shares of NASDAQ:CGEN remained flat at $1.64 during midday trading on Tuesday. 111,379 shares of the stock were exchanged, compared to its average volume of 405,621. The firm has a market capitalization of $146.35 million, a price-to-earnings ratio of -16.40 and a beta of 2.64. Compugen has a 1 year low of $0.53 and a 1 year high of $3.03. The firm has a fifty day moving average price of $1.81 and a two-hundred day moving average price of $1.89.

Analysts Set New Price Targets

Separately, StockNews.com upgraded shares of Compugen from a "hold" rating to a "buy" rating in a research report on Thursday, August 15th.

Compugen Company Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.